Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. MediWound Ltd.
  6. Company
    MDWD   IL0011316309

MEDIWOUND LTD.

(MDWD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
MediWound Ltd. is a Israel-based biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Number of employees : 75 people.
Sales per Business
20192020Delta
Biopharmaceutical Products31.79100%21.76100% -31.54%
USD in Million
Sales per region
20192020Delta
United States28.5089.7%18.0382.8% -36.75%
European Union and Other International Markets3.2910.3%3.7317.2% +13.64%
USD in Million
Managers
Name Title Age Since
Sharon Malka Chief Executive Officer 48 2019
Boaz Gur-Lavie Chief Financial Officer 47 2019
Lior Rosenberg, Dr. Chief Medical Officer 75 2013
Ety Klinger, Dr. Chief Research & Development Officer 59 2014
Vickie R. Driver, Dr. Independent Director 67 2017
Stephen T. Wills Executive Chairman 64 2020
Nissim Mashiach Independent External Director 60 2017
Sharon Kochan Independent External Director 53 2017
Yaron Meyer Corporate Secretary & General Counsel 42 2013
Keren David-Zarbiv Vice President-Clinical Affairs - 2013
Members of the board
Name Title Age Since
Stephen T. Wills Executive Chairman 64 2020
Ofer Gonen Director 47 2003
Vickie R. Driver, Dr. Independent Director 67 2017
Nissim Mashiach Independent External Director 60 2017
Sharon Kochan Independent External Director 53 2017
Assaf Segal Director 50 2017
Samuel J. Moed Director 59 2020
David Fox Director 63 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 27,247,096 15,584,864 57.2% 0 0.0% 57.2%
Shareholders
NameEquities%
Migdal Makefet Pension & Provident Funds Ltd. 1,909,112 7.01%
Lior Rosenberg 1,853,905 6.80%
ARK Investment Management LLC 764,876 2.81%
Parian Global Management LP 688,977 2.53%
Massachusetts Financial Services Co. 492,959 1.81%
Broadfin Capital LLC 477,100 1.75%
Uniplan Investment Counsel, Inc. 472,211 1.73%
Renaissance Technologies LLC 470,322 1.73%
Sharon Malka 378,772 1.39%
BOKF, NA (Investment Management) 363,002 1.33%
Company contact information
MediWound Ltd.
42 Hayarkon Street
Yavne, HaMerkaz 8122745

Phone : +972.77.971.4100
Fax : +972.77.971.4111
Web : http://www.mediwound.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of MediWound Ltd.